Study reviews cardiovascular side effects linked to antiviral therapies for COVID-19, highlighting the need for careful ...
J&J has said it will now need upfront payment in full for its anticoagulant Xarelto (rivaroxaban) and immunology therapy Stelara (ustekinumab), with a rebate paid later, rather than the previous ...
Pfizer-partnered anticoagulant Xarelto (rivaroxaban), meanwhile, contributed $1.11 billion in the same period, while J&J booked $1.55 billion from sales of blood cancer therapy Imbruvica ...